1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsThis funding opportunity encourages basic, preclinical research and early clinical testing of in vivo immune cell engineering approaches to reprogram immune cells within the body for treating various diseases, including cancer, autoimmune, infectious, and age-related diseases.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Small businesses are encouraged to apply through NIH SBIR (R43 and R44) or NIH STTR (R41 and R42) parent announcements. Eligibility for clinical trials depends on the specific NIH institute (e. Confirm the full requirements in the official notice before applying.
The current listing shows not specified (SBIR/STTR Phase I limits up to $700,000 for NCI and NIAID). Verify award ceilings, matching requirements, and allowable costs in the official notice.
Applications for Next-generation Cellular Immunotherapy: Reprogramming Immune Cells Inside the Body are due September 2, 2028. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Next-generation Cellular Immunotherapy: Reprogramming Immune Cells Inside the Body is funded by National Institutes of Health (NIH) - National Cancer Institute (NCI), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institute of Dental and Craniofacial Research (NIDCR). Verify program details on the funder's official page before applying.
Past winners and funding trends for this program
The memorandum of agreement was signed August 4 and 5, disclosed by House appropriators on September 3, and runs through 2036. It names no dollar figure. Here is what is actually established, what is still speculation, and what researchers holding or planning NIAID biodefense awards should do before September 30.
Read articlePAR-27-062 creates a three-year, $80,000-salary postdoctoral career award across NCI, NIAID, NIBIB, NIDCR and NINDS — and it carries a hard eligibility window that closes two years after you start your postdoc. Full analysis of the Academic Career Excellence Award, what it replaces, and why the timing rule is the whole competition.
Read articleThe NIH Common Fund launched PRIMED-AI — Precision Medicine with AI: Integrating Imaging with Multimodal Data — as five coordinated funding opportunities (RFA-RM-27-011 through -015) that build a full pipeline from standards to clinic. Here is how the Playbook, Data-to-Model partnerships, Model-to-Clinic translation, Validation Center, and Logistics Center fit together, what each pays, who is eligible, and how to position before the October 2026 deadlines.
Read article